This course is part of the The Future of Alzheimer Disease: Early Recognition and Emerging Therapy curriculum.
0.50 CME Credit
New and Emerging Therapies for Alzheimer DiseaseAn Interactive Learning ExperienceThis course is hosted by an external partner. By clicking Launch Course, you will be directed off of Pri-Med.com. Upon completing the activity, you will be prompted to return to Pri-Med.com
In this AdaptED learning module, the adaptive learning algorithm will employ Alzheimer disease (AD) neuropathology as a backdrop to explore various promising mechanisms of action for new and emerging disease-modifying therapies, such as those targeting β-amyloid, tau, inflammation, central nervous system glucose metabolism, bioenergetics, and synaptic plasticity. The activity will focus on anti-amyloid antibodies in late phases of development, under FDA review, or that have recently received an FDA indication to treat AD. The education will dive into the clinical efficacy, safety, tolerability, and administration of these agents and will identify which patients are most likely to benefit from taking them.
0.50 AMA PRA Category 1 Credits, 0.50 ABIM MOC or 0.50 AANP, including 0.50 AANP Pharm
Release Date: 6/10/2022
Expiration Date: 6/10/2023
- Explore the mechanism of action of new and emerging disease-modifying therapies for Alzheimer disease (AD)
- Explore the evidence supporting new and emerging disease-modifying therapies for AD and consider which patients are most likely to benefit from these therapies
Gad A. Marshall, MD
Associate Professor of Neurology Harvard Medical School Associate Medical Director of Clinical Trials Center for Alzheimer Research and Treatment Brigham and Women's Hospital Assistant in Neurology Massachusetts General Hospital Boston, MALearn More
The following relevant financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute.
Gad A. Marshall, MD: Independent Contractor for Eisai, Genentech, and Lilly.
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.
AMA PRA Category 1 Credits
Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Pri-Med Institute designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pri-Med Institute is accredited by the American Association of Nurse Practitioners® as an approved provider of nurse practitioner continuing education. Provider number: 040308.
This activity is approved for 0.50 contact hours of continuing education, which includes 0.50 hours of pharmacology.
MOC Credit Information
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Supporters and Partners
This activity is supported by an educational grant from Lilly
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients. Data, indications, and guidelines presented in this activity are current as of the activity release date and they are subject to change as new information is published.
Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. Pri-Med Institute is the accredited provider for this activity.
Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.
Questions? If you have questions about this activity, please email email@example.com or call (877) 477-4633.